Off-label dantrolene sodium therapy markedly improved clinical symptoms, enhanced muscle relaxation, and reduced exercise-induced stiffness in a patient with rare Brody myopathy.
Does dantrolene sodium improve symptoms in a patient with Brody myopathy?
Off-label use of dantrolene sodium may provide symptomatic relief and improve functional capacity in patients with rare Brody myopathy.
Absolute Event Rate: 0% vs 0%
ABSTRACT Background: Brody myopathy is a rare autosomal recessive disorder caused by mutations in the ATP2A1 gene, which encodes for sarcoplasmic reticulum Ca++–ATPase (SERCA1) pump in the fast twitch skeletal muscle fibers. Case Presentation: Patient is a 19-year-old woman presenting with exercise-induced rhabdomyolysis. Genetic testing confirmed a pathologic ATP2A1 mutation affecting SERCA1 function in type 2 muscle fibers. The patient experienced significant functional limitations due to impaired calcium reuptake and prolonged muscle contraction. Management and Outcome: Treatment with dantrolene sodium resulted in marked clinical improvement. The patient demonstrated enhanced muscle relaxation, reduced exercise-induced stiffness, and improved functional capacity following dantrolene therapy. Conclusion: This case demonstrates the therapeutic efficacy of dantrolene (off-label) in managing Brody myopathy symptoms. Given the rarity of this condition, further documentation of successful treatment strategies is crucial for establishing evidence-based management protocols for patients with ATP2A1-related myopathy.
Sara J. Edmund (Wed,) reported a other. Off-label dantrolene sodium therapy markedly improved clinical symptoms, enhanced muscle relaxation, and reduced exercise-induced stiffness in a patient with rare Brody myopathy.